Vasoreactivity Testing: Procedure, Results, and Safety

Vasoreactivity testing is a set of clinical procedures that measure how blood vessels respond when exposed to specific drugs or physiological challenges. The test is most widely used during right heart catheterization in people with pulmonary arterial hypertension, where it helps clinicians determine whether a patient’s lung blood vessels can still relax in response to a vasodilator, but the concept extends well beyond the lungs. Variants of the test are performed on coronary arteries, cerebral blood vessels, and peripheral arteries, each with different agents, thresholds, and clinical goals.

Why the Test Exists

Blood vessels are not rigid pipes. Their walls contain smooth muscle cells that contract and relax in response to chemical signals, nerve impulses, and the inner lining of the vessel itself. When disease disrupts that dynamic responsiveness, vessels can become chronically narrowed or unable to dilate when the body needs more blood flow. Vasoreactivity testing essentially asks a vessel: can you still open up? The answer guides treatment decisions in ways that blood pressure readings alone cannot.

Pulmonary arterial hypertension, the condition most tightly linked to vasoreactivity testing, involves progressive narrowing of the small arteries in the lungs driven by abnormal vascular tone, structural remodeling of the vessel wall, and intraluminal obstruction.¹ In some patients, a significant portion of that narrowing stems from excessive smooth-muscle contraction rather than permanent scarring. Those patients respond remarkably well to calcium channel blockers, which are cheaper, easier to administer, and better tolerated than the more aggressive therapies used for the disease. Vasoreactivity testing is how clinicians sort out who those patients are.

How the Pulmonary Test Is Performed

During a right heart catheterization, a thin pressure-sensing catheter is threaded through a vein, typically in the neck or groin, and advanced into the pulmonary artery. Baseline pressures are recorded, including the mean pulmonary artery pressure and cardiac output. A short-acting vasodilator is then administered, and the same measurements are repeated within minutes. The preferred agents are inhaled nitric oxide and intravenous epoprostenol, both endorsed by major consensus guidelines.² Some centers use adenosine as an alternative.³

The choice of agent matters because the test relies on a drug that is potent enough to reveal residual vasodilator capacity but clears the body quickly, minimizing any lingering effects on the hemodynamic measurements. Nitric oxide, for instance, is inhaled as a gas, acts almost instantly on pulmonary smooth muscle, and is inactivated within seconds once breathing returns to normal. Epoprostenol, given intravenously, has a half-life measured in minutes. These pharmacological properties make it possible to run the test and return to a stable baseline in a single catheterization session.

Defining a Positive Response

A patient is considered a “responder” when the mean pulmonary artery pressure drops by at least 10 mmHg to reach an absolute value below 40 mmHg, without any decrease in cardiac output.⁴ That last condition is critical: a pressure drop caused by the heart pumping less blood does not indicate genuine vasodilation and would be a misleading result. The threshold sounds specific, and it is meant to be. Earlier, looser definitions produced false optimism, identifying patients as vasoreactive who did not actually benefit from calcium channel blocker therapy over the long term.

Roughly one in ten patients with idiopathic pulmonary arterial hypertension meets these criteria. The proportion is even smaller in patients whose hypertension is associated with connective tissue diseases or congenital heart defects. When a patient does test positive and is started on high-dose calcium channel blockers, the clinical benefit can be substantial and sustained. But not everyone who tests positive on the initial catheterization remains a long-term responder, which is one reason follow-up testing is increasingly discussed.

Follow-Up Testing and Prognosis

A single vasoreactivity test captures a snapshot, but the disease can evolve. Researchers have examined whether repeating the test months or years after diagnosis adds prognostic information. In one study with a median follow-up of over six years, patients who lost their vasoreactive response on a follow-up catheterization had dramatically worse survival compared to those who maintained it.⁵ Losing vasoreactivity, defined as a mean pulmonary artery pressure that no longer drops during the challenge, was an independent predictor of death even after adjusting for age and other known prognostic factors.

Separate work looking at nitric oxide with oxygen as the test agent found that patients whose pulmonary vascular resistance fell by at least 30 percent during the test had about half the mortality risk over the following years, and this relationship held even among patients who were never treated with calcium channel blockers.⁶ In other words, the degree of vasoreactivity is not just a treatment-selection tool; it appears to be a biological marker of disease severity in its own right. A vessel bed that can still relax is one that retains some functional reserve, and that reserve seems to translate into longer survival regardless of the therapeutic path chosen.

Pediatric and Congenital Heart Disease Considerations

Vasoreactivity testing is not limited to adults. Children with pulmonary hypertension undergo the same general procedure, but the criteria for a positive result are adjusted. In pediatric patients with pulmonary arterial hypertension associated with congenital heart defects and left-to-right shunts, the test is used to assess whether a child is a surgical candidate for shunt closure. The hemodynamic targets differ from the adult definition: a positive response requires a fall in indexed pulmonary vascular resistance of more than 20 percent, with the final value below 6 indexed Wood units.⁷

The stakes in this population are particularly high. If a child with a ventricular septal defect or other shunt lesion has irreversibly elevated pulmonary vascular resistance, closing the defect can be catastrophic because the right ventricle loses its “pop-off valve” and faces an afterload it cannot handle. Vasoreactivity testing provides some reassurance that the elevated pressures are at least partly reversible. International surveys suggest that practice still varies from center to center in terms of which agents are used and how results are interpreted in children, reflecting the fact that pediatric pulmonary hypertension is rare enough that large, definitive trials are difficult to conduct.

Coronary Vasoreactivity Testing

A completely different branch of vasoreactivity testing takes place in the coronary arteries. Many patients present with chest pain, undergo standard angiography, and are told their coronary arteries look normal. In a significant portion of these patients, the problem lies not in blockages visible on an angiogram but in abnormal behavior of the vessel wall itself. Coronary vasoreactivity testing is designed to unmask these functional disorders.

The most established method uses intracoronary acetylcholine, injected in graded doses directly into the coronary arteries during catheterization. Acetylcholine has a dual nature: in a healthy vessel, it triggers the endothelial lining to release nitric oxide, causing dilation, while in a dysfunctional vessel, it bypasses the endothelium and acts directly on smooth muscle to cause constriction. This makes it a powerful diagnostic agent. Intracoronary acetylcholine testing can identify both endothelial dysfunction, a subtler impairment, and frank coronary artery spasm, a more dramatic constriction that can cause angina and ischemic changes on the electrocardiogram.⁸

Ergonovine, another provocative agent, has also been used historically to induce coronary spasm. In patients with vasospastic angina, both acetylcholine and ergonovine can reliably reproduce the spasm seen clinically, and in most cases they provoke constriction at the same coronary site and to the same degree.⁹ However, in a small subset of patients, acetylcholine can paradoxically relieve a spontaneous spasm rather than provoke one, meaning ergonovine is sometimes needed as a confirmatory test. Protocols for acetylcholine dosing have been refined over time, with research suggesting that in patients showing minimal constriction at lower doses, higher doses can sometimes be omitted safely.¹⁰

A related but distinct assessment targets the coronary microcirculation, the tiny vessels that angiography cannot visualize. Here, adenosine is injected into the coronary artery to induce maximum dilation, and coronary flow reserve is measured. A flow reserve below 2.5 is considered diagnostic for microvascular dysfunction that is not dependent on the endothelium.¹¹ Because epicardial spasm and microvascular dysfunction can coexist but require different treatments, a thorough evaluation often combines both acetylcholine provocation and adenosine-based flow assessment in the same session.

Safety of Invasive Coronary Function Testing

Any procedure involving injecting vasoconstrictors into coronary arteries raises safety concerns. Large real-world registries have been reassuring. A Dutch registry of over a thousand invasive coronary function tests reported a major complication rate of 0.9 percent, with no fatal events. Transient conduction disturbances in the heart’s electrical system were common, occurring in about a quarter of patients, but were self-limiting. Atrial fibrillation appeared in roughly 4 percent of cases and also resolved on its own. Intravenous atropine to stabilize heart rhythm or reverse persisting spasm was needed in fewer than 2 percent of procedures.¹² A Belgian registry found even lower complication rates, with major complications at 0.7 percent for microvascular physiology assessment and zero percent for the vasoreactivity portion of the test specifically.¹³

These numbers suggest that when performed at experienced centers, invasive coronary vasoreactivity testing carries a risk profile comparable to standard diagnostic angiography. The main practical barrier is not danger but availability. The procedure requires specific expertise, on-hand supplies of acetylcholine (which is not stocked at many catheterization labs), and familiarity with the interpretation of functional results that go beyond simply looking for anatomical blockages.

Non-Invasive Approaches

Not all vasoreactivity testing requires a catheter inside a blood vessel. In the peripheral circulation, the flow-mediated dilation test has become the most widely used non-invasive assessment of vascular endothelial function in humans since its development in 1992.¹⁴ The test works by inflating a blood pressure cuff on the forearm for several minutes, cutting off blood flow, then releasing it. The resulting rush of blood creates shear stress on the vessel wall, and a healthy endothelium responds by producing nitric oxide and dilating. An ultrasound probe positioned over the brachial artery measures how much the artery’s diameter increases.¹⁵

Flow-mediated dilation has found extensive use in research settings as a surrogate marker for cardiovascular risk. People with conditions that damage the endothelium, such as diabetes, smoking, and hypertension, tend to have blunted dilation responses. However, the technique has limitations in clinical practice. Measurements are highly operator-dependent, sensitive to room temperature, caffeine intake, and time of day, and there is no universally agreed-upon cutoff that separates “normal” from “abnormal.” One comparison study found that patients with peripheral arterial disease had significantly lower flow-mediated dilation than healthy subjects, but an alternative finger-based technique called peripheral artery tonometry did not detect the same difference, and the two methods showed no meaningful correlation with each other.¹⁶ This disconnect underscores a broader challenge: different non-invasive methods are measuring different aspects of vascular function and are not interchangeable.

Emerging imaging approaches have also been explored. Coronary magnetic resonance angiography has shown promise for tracking how the coronary arteries dilate in response to sublingual nitroglycerin, offering a potential non-invasive window into coronary vasomotion without catheterization.¹⁷ This technique remains experimental, but it hints at a future where at least some aspects of coronary vasoreactivity could be assessed without invasive procedures.

Cerebrovascular Vasoreactivity

The brain’s blood vessels have their own version of vasoreactivity testing, aimed at measuring how well the cerebral circulation can adjust blood flow in response to changes in carbon dioxide levels. Carbon dioxide is a potent cerebral vasodilator; when levels rise, the brain’s arteries open wider to maintain adequate oxygen delivery. Impaired cerebrovascular reactivity is seen in conditions like severe carotid artery stenosis, small-vessel disease, and after traumatic brain injury, and it has been associated with increased stroke risk.

The most common non-invasive technique uses transcranial Doppler ultrasound to measure blood flow velocity in the middle cerebral artery while the patient undergoes a carbon dioxide challenge.¹⁸ The challenge can be delivered in different ways: the patient can inhale a gas mixture containing a known concentration of CO₂, or they can simply hold their breath for a set period. Both methods raise blood CO₂ levels and provoke dilation, but they are not perfectly interchangeable. A study of 143 subjects found only moderate correlation between breath-holding and the formal CO₂ inhalation/hyperventilation method, suggesting they capture overlapping but not identical aspects of cerebrovascular reserve.¹⁹

This matters clinically because a patient’s cerebrovascular vasoreactivity may inform decisions about carotid surgery or stenting. If the brain’s vessels on the affected side have already lost the ability to dilate further, it implies they are already maximally compensating for reduced blood flow, a state sometimes described as exhausted vasodilator reserve. These patients may be at higher risk of stroke without intervention.

Laboratory and Research Applications

Outside the clinic, vasoreactivity is studied in the laboratory using ex vivo techniques. The classic approach involves placing small rings of an artery or vein in an organ bath, a chamber filled with a physiological nutrient solution kept at body temperature and aerated with a controlled gas mixture. Researchers then expose the tissue to increasing concentrations of vasoactive drugs while measuring the resulting contraction or relaxation. This generates dose-response curves that reveal whether the endothelium is functioning normally, how sensitive the smooth muscle is to various signals, and how different drugs or disease states alter vascular behavior.²⁰

These experiments have been foundational for understanding the mechanisms behind conditions like atherosclerosis, hypertension, and diabetes-related vascular damage. They also serve as the preclinical testing ground for new drugs. When a pharmaceutical company develops a new vasodilator, ex vivo organ bath studies are among the earliest experiments performed to characterize how the compound interacts with blood vessel physiology before any human testing begins.

Genetic Variability in Vasoreactivity

Not everyone’s blood vessels respond to the same stimulus in the same way, and genetics plays a role in that variability. Research on potassium channel genes has identified genetic variants that may influence how patients with idiopathic pulmonary arterial hypertension respond to nitric oxide during vasoreactivity testing. Specifically, variants in the KCNA5 gene, which encodes a voltage-gated potassium channel expressed in pulmonary artery smooth muscle, have been linked to the degree of pressure reduction achieved during the test.²¹

This line of investigation is still early-stage, but it points toward a future where genetic profiling could supplement or even partially replace invasive hemodynamic testing. If clinicians could predict with reasonable accuracy whether a patient is likely to be vasoreactive based on a blood test, it might reduce the number of catheterizations needed. For now, though, the hemodynamic test remains the gold standard because the genetic associations are not strong or consistent enough to guide therapy on their own. The biology of vasoreactivity involves dozens of interacting pathways, including nitric oxide signaling, prostacyclin, endothelin, calcium handling, and potassium channel activity. A single gene variant captures only a sliver of that complexity.

Standardization Challenges

One of the persistent frustrations in the field is the lack of uniformity across testing protocols. Even within pulmonary vasoreactivity testing, where the definition of a positive response is nominally standardized, there are variations in which drug is used, the dose and duration of administration, and how cardiac output is measured. The American Heart Association has issued scientific statements aimed at standardizing baseline and provocative hemodynamic protocols, covering not just vasodilator challenges but also volume loading and exercise testing during catheterization. These statements acknowledge that without consistent methodology, comparing results across centers or clinical trials becomes unreliable.

The problem is amplified in coronary and cerebrovascular testing, where the diversity of techniques, agents, and endpoints is even wider. Flow-mediated dilation in the brachial artery, acetylcholine provocation in the coronary arteries, adenosine-based microvascular assessment, breath-holding indices in the cerebral circulation: these are all forms of vasoreactivity testing, but they probe different vascular beds, different cell types, and different signaling pathways. A person can have normal peripheral endothelial function and severely impaired coronary microvascular function, or vice versa. Clinicians need to understand which test answers which clinical question, because the results are not transferable across vascular territories.